CoChat

The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.

Current landscape, unmet needs, and future directions for treatment of bipolar depression

Open access
Frye, Mark A., Prieto, Miguel L., Bobo, William V., Kung, Simon, Veldic, Marin, Alarcon, Renato D., Moore, Katherine M., Choi, Doo-Sup, Biernacka, Joanna M., Tye, Susannah J. · 2014 · Journal of Affective Disorders

Abstract

BACKGROUND: Depression is the predominant pole of illness disability in bipolar disorder and, compared with acute mania, has less systematic research guiding treatment development. The aim of this review is to present the therapeutic options currently available for managing bipolar depression and to highlight areas of unmet need and future research. METHODS: Literature search of PubMed, PsycINFO, and Cochrane databases and bibliographies from 2000 to August 2013 for treatments that have regulatory approval for bipolar depression or early controlled preliminary data on efficacy. RESULTS: Treatment options for bipolar depression have increased over the last decade, most notably with regulatory approval for olanzapine/fluoxetine combination, quetiapine, and lurasidone. Conventional mood stabilizers lamotrigine and divalproex have meta-analyses suggesting acute antidepressant response. Manual-based psychotherapies also appear to be effective in treating bipolar depression. The therapeutic utility of unimodal antidepressants, as a class, for the treatment of patients with bipolar depression, as a group, remains to be confirmed. There is a substantially unmet need to develop new interventions that are efficacious, effective, and have low side effect burden. LIMITATIONS: Additional compounds are currently being developed that may ultimately be applicable to the treatment of bipolar depression and early open-trial data encourage further studies, but both of these topics are beyond the scope of this review. CONCLUSION: Future registrational trials will need to establish initial efficacy, but increasing interest for personalized or individualized medicine will encourage further studies on individual predictors or biomarkers of response.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0165-0327(14)70005-9

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 87 references

Research works printed but not linked: 2

  1. Frye, 2013, Efficacy and safety of armodafinil as an adjunctive therapy for the treatment of a major depressive episode associated with bipolar I disorder, Bipolar Disord., 15, 126
  2. Tye, 2013, Allostatic overload: transcriptomic insights into the molecular basis of antidepressant resistance, Bipolar Disord., 15, 41

Cited by

See all 36

Metadata

Authors
Frye, M. A., Prieto, M. L., Bobo, W. V., Kung, S., Veldic, M., Alarcon, R. D., Moore, K. M., Choi, D.-S., Biernacka, J. M., & Tye, S. J.
Affiliations
  • Mayo Clinic (US)
  • Universidad de Los Andes, Chile (CL)
Corresponding author
Frye, Mark A.
Venue
Journal of Affective Disorders
Publisher
Elsevier BV
Published
2014-12
Volume
169
Pages
S17-S23
ISSN
0165-0327 (ISSN-L)
OpenAlex
W2114940817
Cited by
36
References
87
Citations by year
2025: 3 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 6 · 2016: 4 · 2015: 5
FWCI
0.69
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Affective Disorders (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Universidad Peruana Cayetano Heredia Institutional Repository (publishedVersion)
Funders
Teva Pharmaceutical Industries
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
Keywords
bipolar depression, bipolar disorder, antidepressant treatment, unmet treatment needs, olanzapine-fluoxetine combination, quetiapine, lurasidone, lamotrigine, divalproex, mood stabilizers, personalized medicine, treatment response biomarkers
MeSH terms
Lurasidone Hydrochloride, Quetiapine Fumarate, Lamotrigine, Anticonvulsants, Antidepressive Agents, Benzodiazepines, Bipolar Disorder, Dibenzothiazepines, Drug Combinations, Fluoxetine, Forecasting, Health Services Needs and Demand, Humans, Psychotherapy, Thiazoles, Triazines, Isoindoles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current landscape, unmet needs, and future directions for treatment of bipolar depression. https://app.cochat.ai/papers/10.1016/s0165-0327(14)70005-9
The paper
Frye, M. A., Prieto, M. L., Bobo, W. V., Kung, S., Veldic, M., Alarcon, R. D., Moore, K. M., Choi, D.-S., Biernacka, J. M., & Tye, S. J. (2014). Current landscape, unmet needs, and future directions for treatment of bipolar depression. Journal of Affective Disorders. https://doi.org/10.1016/s0165-0327(14)70005-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.